@Article{,
AUTHOR = {Andrew S. Iskandar, Kevin K. Zarrabi, William J. Tester},
TITLE = {Renal cell carcinoma: entering the age of biomarkers},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {31},
YEAR = {2024},
NUMBER = {4},
PAGES = {11921--11930},
URL = {http://www.techscience.com/CJU/v31n4/59572},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> Renal cell carcinoma is as the most
prevalent form of kidney cancer, with the clear cell subtype
comprising approximately 75% of cases. The identification
of predictive and prognostic biomarkers has emerged
as a crucial area of research within the field. Despite
advancements in treatment, metastatic renal cell carcinoma
presents formidable challenges, with survival rates heavily
dependent upon the optimal choice of treatment.<br/>
<b>Materials and methods:</b> This review summarizes the
current literature regarding the prognostic and predictive
value of biomarkers in patients with renal cell carcinoma.
We conducted a comprehensive literature search to
identify studies that reference biomarkers of interest in
this domain.<br/>
We selected studies based on their relevance, publication
date, and the quality of the research. Data from these
selected papers were compiled and analyzed to provide an overview of the current understanding and advancements
in the field. The findings were then synthesized into a
concise discussion highlighting the state of biomarker
research in renal cell carcinoma today.<br/>
<b>Results and conclusions:</b> While various nucleic acid
and protein biomarkers have shown promise in other
malignancies, their application in renal cell carcinoma
remains limited by the lack of validated predictors.
This review aims to highlight the pressing need for
robust predictive and prognostic biomarkers in renal
cell carcinoma to guide clinicians in tailoring optimal
therapeutic strategies. The discussion encompasses
the limitations of existing markers and underscores the
significance of the most recent advancements within the
field. Despite these strides, the clinical application of
renal cell carcinoma biomarkers requires further study
and validation.},
DOI = {}
}